- Lucid Diagnostics ( NASDAQ: LUCD ) announced on Thursday that its subsidiary, LucidDx Labs, has launched four new Lucid Test Centers in California, Texas, Florida and Ohio.
- Patients in the metropolitan areas with chronic heartburn can order from their own physician or from a telemedicine physician and can now undergo a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer, using Lucid’s EsoGuard DNA Esophageal Test.
- The test centers are staffed with Lucid-employed nurse practitioners who use EsoCheck to collect surface esophageal cells which are sent to LucidDx Labs for EsoGuard testing.
- ( LUCD ) has risen ~2% premarket.
For further details see:
Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio